Compare Stocks → Warning: this could blow your mind (From DTI) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ACSTNYSE:ETXNASDAQ:SBTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACSTAcasti Pharma$3.40$3.00$1.72▼$3.84$31.96M1.4822,746 shs224,147 shsETXEaton Vance Municipal Income 2028 Term Trust$18.05-0.5%$17.97$16.36▼$18.60N/AN/A28,478 shs52,375 shsSBTXSilverback Therapeutics$9.96-0.4%$7.69$2.80▼$8.97$359.14M0.6337,931 shs1.18 million shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACSTAcasti Pharma0.00%0.00%+1.80%+16.84%+31.45%ETXEaton Vance Municipal Income 2028 Term Trust-0.39%-1.63%+0.67%+3.62%+2.32%SBTXSilverback Therapeutics-0.40%+14.48%+19.28%+76.60%+49.55%CBOE shift unlocks new weekend income strategy (Ad)You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend. Check out this training for the full story! MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACSTAcasti Pharma3.5951 of 5 stars3.55.00.00.03.90.81.3ETXEaton Vance Municipal Income 2028 Term TrustN/AN/AN/AN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACSTAcasti Pharma3.00Buy$6.0076.47% UpsideETXEaton Vance Municipal Income 2028 Term TrustN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest ACST, ETX, C4XD, OBD, and SBTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/7/2024ACSTAcasti PharmaCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$6.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACSTAcasti Pharma$200K159.80N/AN/A$9.14 per share0.37ETXEaton Vance Municipal Income 2028 Term Trust$-232.48KN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/A$7.41 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACSTAcasti Pharma-$42.43M-$5.08N/AN/AN/AN/A-13.18%-11.32%6/28/2024 (Estimated)ETXEaton Vance Municipal Income 2028 Term TrustN/AN/A0.00∞N/AN/AN/AN/AN/ASBTXSilverback Therapeutics-$89.48M-$2.42N/A∞N/AN/A-29.62%-28.20%N/ALatest ACST, ETX, C4XD, OBD, and SBTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails2/12/202412/31/2023ACSTAcasti Pharma-$0.23-$0.21+$0.02-$0.21N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACSTAcasti PharmaN/AN/AN/AN/AN/AETXEaton Vance Municipal Income 2028 Term Trust$0.764.21%N/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/ALatest ACST, ETX, C4XD, OBD, and SBTX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date3/1/2024ETXEaton Vance Municipal Income 2028 Term Trustmonthly$0.07825.2%3/20/20243/21/20243/28/20242/1/2024ETXEaton Vance Municipal Income 2028 Term Trustmonthly$0.07825.3%2/21/20242/22/20242/29/20241/2/2024ETXEaton Vance Municipal Income 2028 Term TrustMonthly$0.07805.34%1/22/20241/23/20241/31/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACSTAcasti PharmaN/A15.1915.19ETXEaton Vance Municipal Income 2028 Term TrustN/AN/AN/ASBTXSilverback TherapeuticsN/A67.8767.87OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACSTAcasti Pharma6.08%ETXEaton Vance Municipal Income 2028 Term TrustN/ASBTXSilverback Therapeutics74.89%Insider OwnershipCompanyInsider OwnershipACSTAcasti Pharma13.51%ETXEaton Vance Municipal Income 2028 Term TrustN/ASBTXSilverback Therapeutics34.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableACSTAcasti Pharma329.40 million8.13 millionNot OptionableETXEaton Vance Municipal Income 2028 Term TrustN/AN/AN/ANot OptionableSBTXSilverback Therapeutics8336.06 million23.65 millionNot OptionableACST, ETX, C4XD, OBD, and SBTX HeadlinesSourceHeadlineARS Pharmaceuticals Inc (SPRY)uk.investing.com - May 11 at 1:32 PMWild Isleswwf.org.uk - March 12 at 9:31 AMA look back at RNA Therapeutics – day onepharmaphorum.com - February 24 at 12:35 AMSPRY ARS Pharmaceuticals, Inc.seekingalpha.com - January 24 at 8:04 PMARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After Merger247wallst.com - November 22 at 6:29 AMDr. Sarina Tanimoto Discloses Position in SBTX / Silverback Therapeuticsnasdaq.com - November 18 at 8:19 PMARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxisfinance.yahoo.com - November 10 at 6:41 PMARS Pharmaceuticals Closes Merger with Silverback Therapeuticsfinance.yahoo.com - November 8 at 5:59 PMSilverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic Reactionsmarkets.businessinsider.com - October 28 at 8:15 AMFDA accepts ARS Pharma’s NDA for Neffythepharmaletter.com - October 24 at 10:29 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERIkentuckytoday.com - October 23 at 7:22 PMSilverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxisfinance.yahoo.com - October 21 at 7:59 AMIs Silverback Therapeutics Inc (SBTX) Stock a Good Investment?aaii.com - October 19 at 11:52 AMSHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWNbakersfield.com - October 12 at 11:07 PMINVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBTmarkets.businessinsider.com - September 17 at 5:10 AMSBTX Silverback Therapeutics, Inc.seekingalpha.com - September 15 at 10:58 PMSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBTmarkets.businessinsider.com - September 6 at 11:53 AMSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZYmarkets.businessinsider.com - August 23 at 6:32 PMSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, HNGR, SBTXapnews.com - August 17 at 12:02 PMSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates IEA, BBQ, SBTXapnews.com - August 11 at 1:33 AMSHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing Investigationsmorningstar.com - July 30 at 7:00 AMINVESTIGATION ALERT: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZYapnews.com - July 28 at 2:21 AMShareholder Alert - The M&A Class Action Firm Announces the Investigation of Silverback Therapeutics, Inc. - SBTXbenzinga.com - July 27 at 9:21 PMLifshitz Law PLLC Announces Investigation of IEA, ZY, SBTX, and HNGRapnews.com - July 26 at 9:07 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAcasti PharmaNASDAQ:ACSTAcasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.Eaton Vance Municipal Income 2028 Term TrustNYSE:ETXEaton Vance Municipal Income 2028 Term Trust is a closed ended fixed income mutual fund launched and managed by Eaton Vance Management. It invests in the fixed income markets. The fund invest in stocks of companies operating across the diversified sectors. It was previously known as Eaton Vance Municipal Income Term Trust. Eaton Vance Municipal Income 2028 Term Trust was formed on March 28, 2013 and is domiciled in the United States.Silverback TherapeuticsNASDAQ:SBTXSilverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.